15 PDUFA dates on FDA’s roster in June

FDA is due to make decisions this month on at least six new medicines and nine label expansions. Highlights include the first HER3-targeted antibody-drug conjugate and Sarepta’s DMD gene therapy.

An approval of patritumab deruxtecan from partners Merck & Co. Inc. (NYSE:MRK) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) would make the product first-in-class against HER3...